Patents by Inventor Gerhard Jaehne

Gerhard Jaehne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • C2-substituted idan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals
    Patent number: 7045649
    Abstract: Embodiments of the invention relate to C2-substituted indan-1-ols and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of embodiments of the invention may include compounds of formula I in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for use as anorectics.
    Type: Grant
    Filed: September 22, 2003
    Date of Patent: May 16, 2006
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • C2-substituted indan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals
    Patent number: 7015208
    Abstract: Embodiments of the invention relate to C2-substituted indan-1-ols and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of embodiments of the invention may include compounds of formula I in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for use as anorectics.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: March 21, 2006
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
    Patent number: 7008957
    Abstract: The invention relates to compounds of the formula I in which the radicals have the stated meanings, their stereoisomeric forms and their physiologically tolerated salts and process for their preparation. The compounds are suitable for the treatment of metabohlic disorders such as type 2 diabetes.
    Type: Grant
    Filed: July 26, 2004
    Date of Patent: March 7, 2006
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Holger Wagner, Karl Schoenafinger, Gerhard Jaehne, Holger Gaul, Christian Buning, Georg Tschank, Ulrich Werner
  • Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
    Patent number: 6992067
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: January 31, 2006
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Heiner Glombik, Werner Krame, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schäfer
  • C2-disubstituted indan-1-ol compounds, their derivatives, processes for their preparation, and their use as pharmaceuticals
    Patent number: 6982353
    Abstract: The present invention is directed to C2-disubstituted indan-1-ol systems of the Formula I, physiologically acceptable salts and physiologically functional derivatives thereof, and pharmaceutical compositions comprising such compounds, salts, and derivatives, which are useful for reducing weight, for the prophylaxis or treatment of obesity, and for the prophylaxis or treatment of type II diabetes in mammals. The invention is directed also to methods for reducing weight and such treatments and prophylaxis. The invention is directed also to processes for the preparation of such compounds.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: January 3, 2006
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias G ssel
  • Substituted indoles
    Publication number: 20050282866
    Abstract: Compounds of the formula I are suitable for preparing pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of NF?B is involved.
    Type: Application
    Filed: July 22, 2005
    Publication date: December 22, 2005
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Olaf Ritzeler, Hans Stilz, Bernhard Neises, Gerhard Jaehne, Joerg Habermann
  • Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
    Publication number: 20050267038
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Application
    Filed: June 17, 2005
    Publication date: December 1, 2005
    Inventors: Heiner Glombik, Werner Krame, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schafer
  • Use of C2-substituted indan-1-one systems for preparing medicaments for the treatment of obesity
    Patent number: 6946492
    Abstract: Embodiments of the invention relate to methods of reducing weight in mammals and for the prophylaxis or treatment of obesity comprising administration of C2-substituted indan-1-one systems and their physiologically acceptable salts and physiologically functional derivatives. Compounds for use in methods of embodiments of the invention may include compounds of the formula in which the radicals are as defined, and their physiologically acceptable salts.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: September 20, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Indole derivatives or benzimidazole derivatives for modulating IkB kinase
    Publication number: 20050197353
    Abstract: The present invention relates to indole derivatives or benzimidazole derivatives, to processes for preparing such compounds, to pharmaceutical compositions comprising such compounds, and methods for the prophylaxis and therapy of a disease associated with an increased activity of I?B kinase comprising administering such compounds.
    Type: Application
    Filed: August 18, 2003
    Publication date: September 8, 2005
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Olaf Ritzeler, Gerhard Jaehne
  • Derivatives of C2-substituted indan-1-ol systems for the prophylaxis or treatment of obesity
    Patent number: 6919380
    Abstract: Derivatives of C2-substituted indan-1-ol compounds of formula I: its physiologically acceptable salts, and its physiologically functional derivatives for the prophylaxis or treatment of obesity are disclosed herein. Compositions comprising the same, methods for preparing the instant compounds, and methods for reducing weight in mammals and for the prophylaxis or treatment of obesity are also described.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: July 19, 2005
    Assignee: Aventis Pharma Deutschland GmbH.
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • C2-substituted idan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals
    Publication number: 20050113595
    Abstract: Embodiments of the invention relate to C2-substituted indan-1-ols and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of embodiments of the invention may include compounds of formula I in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for use as anorectics.
    Type: Application
    Filed: November 4, 2004
    Publication date: May 26, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • C2-substituted idan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals
    Publication number: 20050101798
    Abstract: Embodiments of the invention relate to C2-substituted indan-1-ols and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of embodiments of the invention may include compounds of formula I in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for use as anorectics.
    Type: Application
    Filed: September 22, 2003
    Publication date: May 12, 2005
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Use of C2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity
    Publication number: 20050080057
    Abstract: Embodiments of the invention relate to methods of reducing weight in mammals and for the prophylaxis or treatment of obesity comprising administration of of C2-substituted indan-1-ol systems and their physiologically acceptable salts and physiologically functional derivatives. Compounds for use in the methods of the embodiments of the invention include compounds of the formula (I) in which the radicals are as defined, and their physiologically acceptable salts.
    Type: Application
    Filed: December 7, 2004
    Publication date: April 14, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
    Publication number: 20050059716
    Abstract: The invention relates to compounds of the formula I in which the radicals have the stated meanings, their stereoisomeric forms and their physiologically tolerated salts and process for their preparation. The compounds are suitable for the treatment of metabohlic disorders such as type 2 diabetes.
    Type: Application
    Filed: July 26, 2004
    Publication date: March 17, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Holger Wagner, Karl Schoenafinger, Gerhard Jaehne, Holger Gaul, Christian Buning, Georg Tschank, Ulrich Werner
  • Novel cyanopyrrolidides, process for their preparation and their use as medicaments
    Publication number: 20050059724
    Abstract: The invention relates to compounds of the formula I in which the radicals have the meanings stated in the text, their stereoisomeric forms, and their physiologically tolerated salts, physiologically functional derivatives and process for their preparation. The compounds are suitable for the treatment of disorders of metabolism, such as type 2 diabetes.
    Type: Application
    Filed: July 26, 2004
    Publication date: March 17, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Karl Schoenafinger, Holger Wagner, Gerhard Jaehne, Holger Gaul, Christian Buning, Georg Tschank, Ulrich Werner
  • Nover diphenylazetidinone with improved physiological properties, process for its preparation, medicaments comprising this compound, and its use
    Publication number: 20050020563
    Abstract: The invention relates to the compound of the formula 1 and to its physiologically acceptable salts. The compound is suitable, for example, as a hypolipidemic.
    Type: Application
    Filed: March 31, 2004
    Publication date: January 27, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Wendelin Frick, Andreas Lindenschmidt, Stefanie Flohr, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer, Eric Galia, Heiner Glombik
  • Polysubstituted indan-1-ol systems for the prophylaxis or treatment of obesity
    Patent number: 6812257
    Abstract: Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: November 2, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Polysubstituted indan-1-ol systems for the prophylaxis or treatment of obesity
    Patent number: 6812256
    Abstract: Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: November 2, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Substituted indoles
    Publication number: 20040209868
    Abstract: Compounds of the formula I 1
    Type: Application
    Filed: May 11, 2004
    Publication date: October 21, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Olaf Ritzeler, Hans Ulrich Stilz, Bernhard Neises, Gerhard Jaehne, Jorg Habermann
  • C2-substituted idan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals
    Patent number: 6762326
    Abstract: Embodiments of the invention relate to C2-substituted indan-1-ones and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of embodiments of the invention include compounds of formula I in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for use as anorectics.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: July 13, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel